Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Movetis launches constipation drug Resolor in UK

Movetis launches constipation drug Resolor in UK

22nd April 2010

Movetis has made a treatment for chronic constipation in women available to clients in the UK.

The gastrointestinal speciality pharmaceutical company’s treatment Resolor is an enterokinetic agent which targets underlying impaired gut motility in order to provide relief for patients who have proven unresponsive to laxatives.

It was released in Germany earlier this year and has had its safety profile proven over the course of a clinical development programme involving more than 3,000 patients.

Movetis is currently in discussions with the National Institute of Clinical Excellence about conducting a Single Technology Assessment for its new drug.

Dirk Reyn, chief executive officer of Movetis, said: “I am confident that this team too can optimise the full commercial potential of Resolor and further develop our local UK organisation.”

The company is planning to conduct new phase III trials of Resolor over the coming year in order to support its approval as a treatment for male patients, as well as a potential new application as an opioid-induced constipation therapy.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.